physical exercise (20 sit-ups). Patients with concomitant heart disease requiring open surgery were excluded. All patients underwent left heart catheterization and coronary angiography to find the septal branches anatomically "appropriate" for ablation. Criteria for septal arteries "appropriateness" were as follows: the presence of a septal branch (at least 1 mm in diameter) in the proximal part of the left anterior descending (LAD) artery. Anatomical patterns when it was either just one perforator for the whole LAD or a large target septal perforator that supplied blood to the entire length of the interventricular septum (IVS) were excluded, as the risk of an excessive necrosis volume, which could have led to severe arrhythmia disorders over the long term, was high. Age was not considered as a contraindication.
Patients' Characteristics
By the beginning of 2017, our clinic performed 182 ASA procedures on 160 patients with obstructive HCM, refractory to drug therapy. Forty of the 160 patients from this cohort (29 males, 13 females) were followed up for over 10 years (they underwent ASA between 2000 and 2008). The mean age was 43.8 AE 13.9 years. The demographic data of the patients are presented in ►Table 2.
Procedural Details
The procedure was performed using a previously described conventional technique. 1, 7 In all cases, the leads of a temporary transvenous pacemaker were placed in the right ventricular apex for the procedural period and at least 3 days after ASA. After inserting the pacemaker leads, 5,000 units of heparin were administrated intravenously. The radial or common femoral arteries were used for arterial access. Note that 6 to 7 F standard guide catheters (Judkins left 4, Amplatz left 2, Extra Back-Up 3,5) were used for left coronary ostium catheterization. Workhorse soft or hydrophilic wires were applied to engage the target septal branch. Over-the-wire balloon catheters 6 to 10 mm long and 1.5 to 2.5 mm in diameter were chosen for occlusion of the target septal branch. Intraoperative transthoracic echocardiography was applied to localize the perfusion zone of the septal branch and to measure the PG noninvasively at rest and after pacing (Brockenbrough-Braunwald-Morrow sign). Also, to assess gradient reduction, invasive hemodynamic monitoring was used. It is a rule that 50% PG reduction should be obtained to inject ethanol. The same dose of ethanol (3 mL) was empirically selected and then intentionally used for ablation as the initial dose (no matter the thickness of the septum or perforator) in all cases. At least 5-minute exposure of ethanol was used. The balloon was then deflated and removed. Coronary angiography was done to ensure the septal artery occlusion. Just one septal branch per procedure was ablated in the study. In the case of multiple perforator patterns with crisscross perfusion of the excessive muscular bulge in LVOT, the procedure was performed in a staged fashion (1 septal branch per procedure). After the procedure, the patients were transferred to the intensive care unit. Electrocardiographic (ECG) monitoring was performed for at least 3 days if an atrioventricular conduction was normal. When a complete heart block was observed after ASA, temporary pacing continued for up to 7 days, with consequent decision made on permanent pacemaker implantation. Echocardiography was done on the next day after the procedure and before discharge. Holter monitoring was accomplished 1 day prior to removal of the temporary pacemaker lead. Patients were followed up 1 year after ASA, then annually with echocardiography, ECG, and Holter monitoring.
Data Collection
Data were obtained from the local database of Sverdlovsk Regional Hospital No.1 and through direct calls to patients or relatives, or their family physician. The Mandatory Health Insurance Fund kindly provided relevant information relating to the long-term survival rate on each patient. 
Ethics
This study was approved by the local ethical committee of Sverdlovsk Regional Hospital No.1.
Results

Procedural Results
The hospital mortality rate was 0%. Technical success was reached in 97.5% of cases (39/40). Periprocedural complications were as follows: left main dissection, which required emergency coronary artery bypass grafting in 1 patient; and femoral pseudoaneurysm, which was managed by open vascular surgery. Permanent pacemakers were implanted in 3 patients (7.5%).
Long-Term Results
The median clinical follow-up was 123 (2-179) months. The long-term 1-, 5-, 10-, and 15-year survival rates were as follows: 97.5% (95% CI, 95.1-99.9%), 92.5% (95% CI, 94.8-90.2%), 85.0% (95% CI, 82.9-87.1%), and 81.3% (95% CI, 79.3-83.3%), respectively. Sudden death was observed in two cases. Two patients died of ischemic stroke. In three cases, the exact cause of death is still unknown.
In the long-term period, one patient underwent elective percutaneous coronary intervention due to stable angina.
Repeated ASAs were performed in 9 cases: in 7 patientsdue to a multiple septal pattern in the proximal part of LAD and crisscross perfusion of the target zone; in 2 casesbecause of high bifurcation (it was not possible to place a balloon without coverage of the counter-lateral branch) of the target septal branch, when during the first ASA one subselected branch was ablated and then during the second stage the counter-lateral branch was also closed. During the long-term follow-up, one patient underwent radiofrequency ablation of the muscular bulge in LVOT. The one sample log rank test did not find any statistical difference in the 15-year survival rate between patients who underwent ASA in our cohort and age-and sex-matched general Russian population (p ¼ 0.11113). The standardized mortality ratio was 1.81 (95% CI, 0.79-4.12) (see ►Fig. 1).
Long-Term Rhythm Disorders
A 23-year-old patient (1/40) experienced 4 episodes of sustained ventricular tachycardia registered by his previously implanted permanent pacemaker after 9-year follow-up. The risk of sudden death during the last visit was 16.8% (HCM sudden cardiac death [SCD] risk score). He was referred for implantable cardioverter-defibrillator (ICD) implantation.
In the long-term period, permanent pacemakers were implanted in two patients due to high-grade atrioventricular block 9 and 11 years after ASA. In the follow-up period, 5 patients experienced new-onset atrial fibrillation (AF) (2 permanent cases and 3 paroxysmal ones), with 1 patient showing permanent AF at baseline.
Treatment Effect
PG at rest and after exertion significantly decreased as compared with its values after 1-and 10-year follow-ups (resting PG at baseline vs. resting PG 1 year after, p < 0.0001; resting PG at baseline vs. resting PG 10 years after, p < 0.0001; exertional PG at baseline vs. exertional PG 1 year after, p < 0.0001; exertional PG at baseline vs. exertional PG 10 years after, p < 0.0001) (see ►Table 3). At the same time, there were no statistical differences between the gradients at 1-and 10-year follow-ups (resting PG 1 year after vs. resting PG 10 years after, p ¼ 0.908; exertional PG 1 year after vs. exertional PG 10 years after, p ¼ 0.531). IVS thickness at the target zone decreased significantly after 1 year and after 10 years (IVS before ASA vs. IVS 1 year after, p < 0.0001; IVS before ASA vs. IVS 10 years after, p < 0.0001; IVS 1 year after vs. IVS 10 years after, p < 0.0001). During the follow-up period, the ejection fraction and left atrium diameter values were stable (without statistically significant changes as compared with baseline ones, p > 0.05). End-diastolic diameter (EDD) did not change between the baseline and 1 year after ASA (p > 0.05), but a negative trend toward the enlargement of EDD was observed between the 1-and 10-year time periods (EDD 1 year after vs. EDD 10 years after, p ¼ 0.033; EDD before ASA vs. EDD 10 years after, p ¼ 0.035).
The heart failure severity (NYHA class) before ASA and 1 year after decreased, but the NYHA functional class remained practically the same between 1-and 10-year follow-ups (before ASA vs. 1 year after, p < 0.0001; before ASA vs. 10 years after, p < 0.0001; 1 year after vs. 10 years after, p > 0.05).
The Canadian Cardiovascular Society functional class of angina pectoris also statistically did not differ between the baseline values and those after 1 year (p > 0.05) and 10 years (p > 0.05). The normality of logs distribution of the variables was then confirmed. This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
Five patients had initial syncopal episodes, 1 experienced syncope in 1 year, and 2 patients at 10-year follow-up.
The 
Sudden Death Risk and ASA Outcomes
In our study, the median of baseline 5-year SCD risk was 4.4 (1.6-24.5)% as assessed by the HCM SCD risk score model. At the same time, 12 patients had a high initial risk of SCD (more than 6%). This high value can be explained by the fact that the model was given in the guidelines of the European Society of Cardiology in 2014 and ASAs in our cohort were performed between 2000 and 2008. Just one patient in our cohort underwent ICD implantation. The HCM SCD risk score model was not initially recommended for use in case of myectomy or ASA, but it was recently validated for a population of patients undergoing septal reduction therapy.
10 After ASA, we found a statistically significant decline of SCD risk down to 2.3 (1.2-13.9)% (p < 0.0001). Despite the fact that SCD risk was still high, excessive annual mortality was not registered in the 15-year follow-up period (in our experience it was 0.7%/year).
Ethanol Dose
One of the key features of our experience is the use of the same dose of ethanol in all cases (3 mL). In case of multiple septal pattern with crisscross blood supply to the excessive muscular LVOT bulge, ASA procedures were performed in a staged fashion (1 branch per procedure). This strategy was chosen empirically. Subsequently, when analyzing the data of the largest North American ASA register, one-stage ablation of several septal branches was identified as an independent predictor of mortality.
11
There are two rules for selecting the dose of ethanol: (1) it should be based either on the septum thickness or (2) on the perforator's diameter. 7 However, the basis of such strategies is expert opinion, and not the evidence. Also, the dose selection strategy (based either on IVS thickness, or septal branch thickness, or one and the same dose) was not tested in various studies (where just groups with different doses of ethanol were compared).
12,13
Generally, during ASA the ethanol dose is selected irrelevant to the volume of the perforator's vascular bed. In the literature, there is no obvious evidence about the necessity of a complete septal artery closure after ethanol injection. And if a need arises to do so, we still do not know which dose, perforator's diameter (or vascular bed) and speed of injection, is adequate to close it with 100% confidence.
In our cohort, two patients with incomplete septal occlusions suffered from residual obstruction, and they had to undergo successful repeated ablation. This problem arouses some controversy. On the one hand, a few authors demonstrated that a low ethanol dose (1-2 mL) was associated with the same reduction of LVOT obstruction. 12, 13 Obviously, a higher dose of ethanol leads to more radical elimination of obstruction. However, the upper limit of the safe dose is not well established (dedicated randomized trial was not done). Recently, Veselka et al identified a dose of 1.5 to 2.5 mL as well-balanced in terms of safety and efficiency based on the data from Euro-ASA registry.
3
We empirically selected a 3-mL dose as the best compromise between the hemodynamical effect and the ability to close the perforator completely, and it was chosen as the universal initial dose.
Comparison with General Age-and Sex-Matched Russian Population
Comparing the long-term outcomes of interventions with those of general age-and sex-matched general population is a current typical technique used in observational studies. This technique was described in detail by Finkelstein et al. 8 Since the one-sample log-rank test is often not presented in popular statistical packages, the Centre of Biostatistics in MGH developed a special free Microsoft Excel application, which included the test itself and also data on the U.S. population as a control. To compare our cohort with the Russian population, the "death rate" values of the U. 14 
Sorajja et al from Mayo
Clinic also demonstrated comparable survival rates of patients who underwent ASA with expected survival in the natural population of the United States (p ¼ 0.64); the median follow-up was 5.7 years (maximum 11.9 years). 15 Jensen et al also showed that the survival rate of patients after ASA did not statistically differ significantly (p ¼ 0.06) from that of the general population of Denmark during the follow-up period 3.7 (IQR, 1.4-6.3) years.
16
We intentionally examined a cohort of patients who had been operated on at least 10 years before to be able to evaluate the patients' 15-year survival function after ASA, given the lack of long-term data. The median follow-up period was 123 (2-179) months.
The one-sample log-rank test did not find statistically significant differences between the 15-year survival rates in our cohort and the age-and sex-matched general Russian population (p ¼ 0.11113).
Limitations
This is a retrospective observational study with inherent limitations of this type of studies. Taking into account a small cohort of patients, the findings from the statistical analysis cannot be extrapolated to other patient populations but may prove promising for further research.
Conclusions
ASA is safe and efficient during a 15-year follow-up period. Alcohol septal ablation provides long-term survival rates that look comparable with those typical of age-and sexmatched general population.
